These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 33786826

  • 1. Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure.
    Maggioni AP, Dondi L, Andreotti F, Calabria S, Iacoviello M, Gorini M, Gonzini L, Piccinni C, Ronconi G, Martini N.
    Eur J Clin Invest; 2021 Aug; 51(8):e13551. PubMed ID: 33786826
    [Abstract] [Full Text] [Related]

  • 2. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry.
    Rossignol P, Lainscak M, Crespo-Leiro MG, Laroche C, Piepoli MF, Filippatos G, Rosano GMC, Savarese G, Anker SD, Seferovic PM, Ruschitzka F, Coats AJS, Mebazaa A, McDonagh T, Sahuquillo A, Penco M, Maggioni AP, Lund LH, Heart Failure Long-Term Registry Investigators Group.
    Eur J Heart Fail; 2020 Aug; 22(8):1378-1389. PubMed ID: 32243669
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure.
    Polson M, Lord TC, Kangethe A, Speicher L, Farnum C, Brenner M, Oestreicher N, Alvarez P.
    J Manag Care Spec Pharm; 2017 Apr; 23(4-a Suppl):S2-S9. PubMed ID: 28436256
    [Abstract] [Full Text] [Related]

  • 5. A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure.
    Ward T, Lewis RD, Brown T, Baxter G, de Arellano AR.
    BMC Nephrol; 2023 Mar 09; 24(1):47. PubMed ID: 36890464
    [Abstract] [Full Text] [Related]

  • 6. Effects of hyperkalaemia and non-adherence to renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity-matched study.
    Volterrani M, Perrone V, Sangiorgi D, Giacomini E, Iellamo F, Degli Esposti L, on the behalf of a LHUs Study Group (see Appendix).
    Eur J Heart Fail; 2020 Nov 09; 22(11):2049-2055. PubMed ID: 33459467
    [Abstract] [Full Text] [Related]

  • 7. Hyperkalaemia-related reduction of RAASi treatment associates with more subsequent inpatient care.
    Svensson MK, Murohara T, Lesén E, Arnold M, Cars T, Järbrink K, Chen G, Morita N, Venkatesan S, Kanda E.
    Nephrol Dial Transplant; 2024 Jul 31; 39(8):1258-1267. PubMed ID: 38253386
    [Abstract] [Full Text] [Related]

  • 8. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
    Pitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, Christ-Schmidt H, Berman L, Weir MR.
    Eur J Heart Fail; 2015 Oct 31; 17(10):1057-65. PubMed ID: 26459796
    [Abstract] [Full Text] [Related]

  • 9. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
    Linde C, Bakhai A, Furuland H, Evans M, McEwan P, Ayoubkhani D, Qin L.
    J Am Heart Assoc; 2019 Nov 19; 8(22):e012655. PubMed ID: 31711387
    [Abstract] [Full Text] [Related]

  • 10. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.
    Rosano GMC, Tamargo J, Kjeldsen KP, Lainscak M, Agewall S, Anker SD, Ceconi C, Coats AJS, Drexel H, Filippatos G, Kaski JC, Lund L, Niessner A, Ponikowski P, Savarese G, Schmidt TA, Seferovic P, Wassmann S, Walther T, Lewis BS.
    Eur Heart J Cardiovasc Pharmacother; 2018 Jul 01; 4(3):180-188. PubMed ID: 29726985
    [Abstract] [Full Text] [Related]

  • 11. Hyperkalaemia in Heart Failure-Pathophysiology, Implications and Therapeutic Perspectives.
    Llubani R, Vukadinović D, Werner C, Marx N, Zewinger S, Böhm M.
    Curr Heart Fail Rep; 2018 Dec 01; 15(6):390-397. PubMed ID: 30421355
    [Abstract] [Full Text] [Related]

  • 12. Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN.
    Chinnadurai R, Rengarajan S, Budden JJ, Quinn CM, Kalra PA.
    Am J Nephrol; 2023 Dec 01; 54(9-10):408-415. PubMed ID: 37725919
    [Abstract] [Full Text] [Related]

  • 13. Associations between serum potassium and adverse clinical outcomes: A systematic literature review.
    Palaka E, Grandy S, Darlington O, McEwan P, van Doornewaard A.
    Int J Clin Pract; 2020 Jan 01; 74(1):e13421. PubMed ID: 31532067
    [Abstract] [Full Text] [Related]

  • 14. Hyperkalaemia in Heart Failure: Consequences for Outcome and Sequencing of Therapy.
    Murphy D, Banerjee D.
    Curr Heart Fail Rep; 2022 Aug 01; 19(4):191-199. PubMed ID: 35704263
    [Abstract] [Full Text] [Related]

  • 15. Serum potassium abnormalities, renin-angiotensin-aldosterone system inhibitor discontinuation, and clinical outcomes in patients with chronic cardiovascular, metabolic, and renal conditions: A population-based analysis.
    Jiménez-Marrero S, Cainzos-Achirica M, Monterde D, Vela E, Enjuanes C, Yun S, Garay A, Moliner P, Corbella M, Jovells-Vaqué S, Alcoberro L, Pons-Riverola A, Ramos-Polo R, Morillas H, Gómez-Hospital JA, Comin-Colet J.
    Eur J Intern Med; 2024 Jul 01; 125():89-97. PubMed ID: 38548513
    [Abstract] [Full Text] [Related]

  • 16. Epidemiology and risk factors for hyperkalaemia in heart failure.
    Grobbee DE, Filippatos G, Desai NR, Coats AJS, Pinto F, Rosano GMC, Cleland JGF, Kammerer J, de Arellano AR.
    ESC Heart Fail; 2024 Aug 01; 11(4):1821-1840. PubMed ID: 38439165
    [Abstract] [Full Text] [Related]

  • 17. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
    Butler J, Anker SD, Siddiqi TJ, Coats AJS, Dorigotti F, Filippatos G, Friede T, Göhring UM, Kosiborod MN, Lund LH, Metra M, Moreno Quinn C, Piña IL, Pinto FJ, Rossignol P, Szecsödy P, Van Der Meer P, Weir M, Pitt B.
    Eur J Heart Fail; 2022 Jan 01; 24(1):230-238. PubMed ID: 34800079
    [Abstract] [Full Text] [Related]

  • 18. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
    Beusekamp JC, Tromp J, Cleland JGF, Givertz MM, Metra M, O'Connor CM, Teerlink JR, Ponikowski P, Ouwerkerk W, van Veldhuisen DJ, Voors AA, van der Meer P.
    JACC Heart Fail; 2019 Nov 01; 7(11):970-979. PubMed ID: 31606364
    [Abstract] [Full Text] [Related]

  • 19. [Effect of hyperkalemia and RAASi nonadherence on patients affected by heart failure or chronic kidney disease].
    Degli Esposti L, Perrone V, Giacomini E, Sangiorgi D, Alessandrini D, Santoro A.
    G Ital Nefrol; 2019 Sep 24; 36(5):. PubMed ID: 31580544
    [Abstract] [Full Text] [Related]

  • 20. Optimally managing hyperkalemia in patients with cardiorenal syndrome.
    Wang AY.
    Nephrol Dial Transplant; 2019 Dec 01; 34(Suppl 3):iii36-iii44. PubMed ID: 31800079
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.